Acumen (ABOS) CLO Derek Meisner Receives RSUs and Option Grant

What Happened
Derek M. Meisner, Chief Legal Officer and Corporate Secretary of Acumen Pharmaceuticals, received two equity awards on 2026-01-16: 99,133 restricted stock units (RSUs) and a derivative award covering 148,700 shares (option/derivative). Both awards were granted at $0.00 (no cash paid at grant); the filing reports no immediate sale of shares.

Key Details

• Transaction date: 2026-01-16; Filing date: 2026-01-21 (filed within the Form 4 deadline—two business days—considering the MLK Day holiday).
• 99,133 RSUs granted at $0.00 (F1). RSUs represent a contingent right to one share each and do not involve cash payment at grant.
• 148,700-share derivative award granted at $0.00 (F2). Treated as an option/derivative in the filing.
• Vesting: RSUs vest in three equal annual installments beginning one year after the grant (F1). The derivative award vests in 48 equal monthly installments over four years (F2); both are subject to continued service.
• Shares owned after the transaction: not specified in the filing.
• No indication of a sale, cashless exercise, 10b5-1 plan, or tax-withholding disposition in this filing.

Context
These entries are compensation grants (awards) rather than open-market purchases or sales. RSUs convert to common stock as they vest; the derivative award vests monthly over four years. Such grants are routine executive compensation and do not by themselves indicate immediate buying or selling activity.